European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0298/2024

Submitted by Anonymous (not verified) on 19 June 2026 - 10:33

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0298/2024

Opinion/decision on a Paediatric investigation plan (PIP): Lupkynis, voclosporin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0152/2019

Submitted by Anonymous (not verified) on 19 June 2026 - 10:33

Opinion/decision on a Paediatric investigation plan (PIP): Lupkynis, voclosporin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0152/2019

Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 19 June 2026 - 9:30

Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Semglee, insulin glargine, Date of authorisation: 23/03/2018, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 19 June 2026 - 9:07

Human medicines European public assessment report (EPAR): Semglee, insulin glargine, Date of authorisation: 23/03/2018, Revision: 11, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Stelara, ustekinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0084/2021

Submitted by Anonymous (not verified) on 18 June 2026 - 14:30

Opinion/decision on a Paediatric investigation plan (PIP): Stelara, ustekinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0084/2021

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness